Syros pharmaceuticals ticker

Author: jlhu

August undefined, 2024

WebMar 2, 2024 · Syros Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $-0.75 million for the quarter ended December 2024, missing the Zacks... WebC/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE (Street) CAMBRIDGE MA 02140 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [ SYRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief …

Myelodysplastic Syndrome Market: Analysis of Epidemiology, …

WebMar 24, 2024 · Syros Pharmaceuticals - SYRS - Stock Price Today - Zacks Syros Pharmaceuticals (SYRS) (Delayed Data from NSDQ) $2.74 USD -0.07 (-2.49%) Updated … WebSep 15, 2024 · Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol “SYRS,” and will be led by Syros’ existing management team,... red eyes when i woke up

Syros Pharmaceuticals To Acquire TYME Technologies Nasdaq

WebJul 5, 2024 · CAMBRIDGE, Mass. & BEDMINSTER, N.J.-- (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros … WebMar 27, 2024 · Syros Pharmaceuticals (SYRS) (Real Time Quote from BATS) $3.61 USD +0.01 (0.28%) Updated Feb 28, 2024 10:22 AM ET Add to portfolio Zacks Rank: 3-Hold 3 Style Scores: F Value F Growth C... WebWe are focused on applying this approach to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded current targeted approaches, we are advancing our late-stage clinical pipeline to provide new treatment options. red eyes when i wake

Syros Pharmaceuticals, Inc. Signs License Agreement with TMRC

SYRS - Syros Pharmaceuticals Inc Stock quote - CNNMoney.com

WebA. While ratings are subjective and will change, the latest Syros Pharmaceuticals ( SYRS) rating was a maintained with a price target of $15.00 to $13.00. The current price Syros Pharmaceuticals ... WebMar 31, 2024 · Syros Pharmaceuticals, Inc. Price and Consensus Syros Pharmaceuticals, Inc. Quote. Bottom Line. The stock has also started to move higher lately, adding 36.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to ... red eyes when tiredWeb1 day ago · Price To Cash Flow is a widely used stock evaluation measure. Find the latest Price To Cash Flow for Syros Pharmaceuticals (SYRS) red eyes when you wake up

"WebApr 10, 2024 · Ticker Symbol SYRS Full Company Profile Financial Performance In 2024, SYRS's revenue was $14.88 million, a decrease of -36.65% compared to the previous … " - Syros pharmaceuticals ticker

Syros pharmaceuticals ticker

WebThe price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company). WebApr 7, 2024 · Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. …

Did you know?

WebApr 12, 2024 · Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its quarterly earnings data on Thursday, March, 2nd. The company reported ($1.28) EPS for the quarter, missing … WebNov 7, 2024 · Based in Massachusetts, Syros Pharmaceuticals is a biopharmaceutical business with a market cap of around $82 million. It’s a small company, and sometimes a stock representing a business of this size makes a miraculous 5x or 10x move. On the other hand, it’s not unusual for these types of stocks to get cut in half or even worse than that.

WebMar 2, 2024 · 98,4%. More Financials. Company. Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known … WebApr 10, 2024 · Support: 888-992-3836 Home NewsWire Subscriptions ...

WebFind real-time SYRS - Syros Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. SYRS - Syros Pharmaceuticals Inc Stock quote - … WebFind real-time SYRS - Syros Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.

WebSep 16, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of … red eyes when sickWebComplete Syros Pharmaceuticals Inc. stock information by Barron's. View real-time SYRS stock price and news, along with industry-best analysis. red eyes when highWebGet the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … red eyes white dischargeWebDiscover historical prices for SYRS stock on Yahoo Finance. View daily, weekly or monthly format back to when Syros Pharmaceuticals, Inc. stock was issued. knock swap house programWebSyros Pharmaceuticals, Inc. (SYRS) Stock Price, News, Quote & History - Yahoo Finance U.S. markets open in 6 hours 59 minutes Dow Futures Nasdaq Futures Russell 2000 Futures … Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock discussion in Yahoo … Discover historical prices for SYRS stock on Yahoo Finance. View daily, weekly or … Get the detailed quarterly/annual income statement for Syros Pharmaceuticals, … Find out the direct holders, institutional holders and mutual fund holders for … See the company profile for Syros Pharmaceuticals, Inc. (SYRS) including … See Syros Pharmaceuticals, Inc. (SYRS) stock analyst estimates, including … Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2024 Earnings Call … Find out all the key statistics for Syros Pharmaceuticals, Inc. (SYRS), including … View the basic SYRS option chain and compare options of Syros … Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock quote, history, news and … red eyes with black backgroundWebJul 5, 2024 · (RTTNews) - Syros Pharmaceuticals (SYRS) and TYME Technologies, Inc. (TYME) announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire... red eyes twin darkness dragonWebSyros Pharmaceuticals ( NASDAQ:SYRS ) Full Year 2024 Results Key Financial Results Revenue: US$14.9m (down 37% from FY... Thomson Reuters StreetEvents Q4 2024 Syros … red eyes while teething